RAYSEARCH AND IBA TO INCREASE PROTON THERAPY PRECISION

Collaboration agreement signed on the development of proton treatment planning
system
RaySearch Laboratories AB and IBA (Ion Beam Applications S.A.), the global high
-tech leaders in next generation treatment planning software and proton therapy
technology are pleased to announce a collaboration agreement to further develop
the tools that enable clinicians to better leverage the treatment precision of
proton therapy.

This collaboration aims at enhancing the tools in RaySearch’s treatment planning
system RayStation® for proton treatment modalities (i.e. Double Scattering,
Uniform Scanning, and Pencil Beam Scanning). It will enable clinicians worldwide
to better leverage the power of IBA’s Pencil Beam Scanning in a large variety of
clinical conditions.

Olivier Legrain, Chief Executive Officer of IBA, said: “We understand that
efficient and robust treatment planning solutions are key for the development of
proton therapy in general and of Pencil Beam Scanning in particular. In this
matter, IBA’s philosophy is to provide its clinical partners with the best
software options through an open architecture. Today we are proud to be able to
call RaySearch a partner and add its solutions to our portfolio. This
collaboration will further improve proton treatment delivery to reduce side
effects and increase quality of cancer care.”

Johan Löf, President and CEO of RaySearch Laboratories AB added: “Proton therapy
is a prioritized area for us so we are of course delighted to collaborate with
the leading hardware manufacturer in this field. We will now work closely
together to further refine the tools in RayStation® for planning proton
treatments that are delivered with IBA hardware. Together we will be able to
realize the full potential of proton therapy and offer unmatched treatment
quality to the clinics and their patients. I believe that this will be highly
appreciated by existing RayStation® customers such as WPE in Essen, Germany, as
well as other proton centers around the globe.”

IBA and RaySearch are committed to making Proton Therapy, the most accurate
cancer treatment, available worldwide. IBA is the only supplier to have multiple
centers treating cancer patients with Pencil Beam Scanning (PBS), the most
precise form of Proton Therapy. As of today, IBA teams successfully installed
PBS at Massachusetts General Hospital Burr Proton Therapy Center, Boston, MA,
USA, University of Pennsylvania Health System Roberts Proton Therapy Center,
Philadelphia, PA, USA, CDH Procure’s Proton Therapy Center, Chicago area, USA
and Proton Therapy Center, Prague, Czech Republic. These centers are using PBS
daily in clinical treatments.

PBS is under installation in 5 more IBA centers. Altogether, 20 IBA centers will
be treating with PBS within 2 years.

PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to
precisely target a cancerous tumor by controlling both the intensity and the
spatial distribution of the dose to the millimeter.

The Proton Beam Design module in RaySearch’s treatment planning system
RayStation® already contains tools for treatment planning of double scattered
and uniformly scanned protons, such as a clinically approved Pencil Beam dose
engine and automatic generation of treat-and-protect beams. With input from IBA,
RaySearch will now expand the module with, for example, tools for Pencil Beam
Scanning techniques and Monte Carlo dose calculations.

About Proton Therapy
Proton therapy is increasingly considered the most advanced and targeted cancer
treatment due to its superior dose distribution and fewer side effects. Protons
deposit the majority of their effective energy within a precisely controlled
range and shape, directly within the tumor and sparing healthy surrounding
tissue.
As access to proton therapy increases in Europe and across the world, IBA
continues to demonstrate compassionate innovations with more patient-friendly
treatment rooms and more precise therapies. IBA proton therapy systems account
for more than half of the world’s clinically based proton therapy facilities. To
date they include 13 operational proton therapy centers (35 treatment rooms)
worldwide, and 12 more centers in development (adding 23 treatment rooms).

About IBA
IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company
and the worldwide technology leader in the field of proton therapy. The
Company’s expertise lies in the development of next generation proton therapy
technologies and radiopharmaceuticals that provide oncology care providers with
premium quality services and equipment, including IBA’s leading fully integrated
IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality
Assurance of medical equipment and increased patient safety. Headquartered in
Belgium and employing more than 1,200 people worldwide, IBA currently has
installed systems across Europe and the US and is expanding into emerging
markets. The Company is focused on building sustainable global growth for
investors, providing solutions in the fight against cancer. IBA is listed on the
pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB) and more information can be found at: www.iba-worldwide.com.

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions
into a flexible treatment planning system. It combines unique features such as
multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading
algorithms for IMRT and VMAT optimization and highly accurate dose engines for
photon, electron and proton therapy. The system is built on the latest software
architecture and has a graphical user interface offering state-of-the-art
usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch’s
products are mainly sold through license agreements with leading partners such
as Philips, Nucletron, IBA Dosimetry, Varian and Accuray. To date, 15 products
have been launched through partners and RaySearch’s software is used at over
2,000 clinics in more than 30 countries. In addition, RaySearch offers the
proprietary treatment planning system RayStation® directly to clinics. RaySearch
was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and
the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com


For further information, please contact:

Thomas Ralet, Vice-President Corporate Communication, IBA
Telephone: +32 10 475 890
communication@iba-group.com

M:Communications (Media & investor enquiries IBA)
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
Telephone: +44 (0) 207 920 2333
IBA@mcomgroup.com

Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com